

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Currently Amended). ~~A purified nucleic acid~~ An expression vector comprising a nucleotide sequence SEQ ID NOS: 1 or 5, wherein said sequences are transcribed into a myofibrillogenesis-inducing RNA (MIR) molecule. -

2. (Currently Amended). ~~The purified nucleic acid~~ The expression vector of claim 1, wherein said nucleotide sequence is transcribed into an RNA molecule having a secondary structure that permits specific binding to at least one MIR-binding protein.

Claims 3-4. (Canceled).

5. (Withdrawn). The purified nucleic acid of claim 1, wherein the nucleotide sequence shares at least 75% sequence identity with SEQ ID NO: 5.

Claim 6-9. (Canceled).

10. (Previously presented). A purified myofibrillogenesis-inducing RNA (MIR) molecule comprising a ribonucleic acid sequence which is fully complementary to a deoxyribonucleic acid sequence of SEQ ID NO: 5 and induces myofibrillogenesis in living cells.

Claims 11-12. (Canceled).

13. (Previously presented). A vector comprising a purified nucleic acid cDNA of SEQ ID NO: 5 that is transcribed into a myofibrillogenesis-inducing RNA (MIR) molecule.

14. (Original). The vector of claim 13, wherein the purified nucleic acid further encodes a MIR-binding protein.

15. (Withdrawn). A method of inducing a cardiac muscle phenotype in a cell, said method comprising the steps of:

- a) providing a cell comprising at least one MIR-binding protein; and
- b) contacting said cell with at least one MIR molecule that specifically binds to said at least one MIR-binding protein, in an amount sufficient to induce a cardiac muscle phenotype in said cell.

16. (Withdrawn). The method of claim 15, wherein said cardiac muscle phenotype comprises formation of myofibrils or rhythmic contraction of the cell.

17. (Withdrawn). The method of claim 15, wherein said MIR-binding protein is selected from the group consisting of MIR-binding proteins having molecular weights of about 11-13 kDa and about 28-30 kDa.

18. (Withdrawn). The method of claim 15, wherein said at least one MIR molecule is encoded by a nucleic acid comprising a sequence that is less than 166 nucleotides in length and shares at least 75% sequence identity with SEQ ID NO: 1.

19. (Withdrawn). The method of claim 15, wherein said at least one MIR molecule is encoded by a nucleic acid comprising a sequence that is at least 167 nucleotides in length and shares at least 75% sequence identity with SEQ ID NO: 5.

20. (Withdrawn). The method of claim 15, wherein said at least one MIR-binding protein is exogenously added to said cell.

21. (Withdrawn). The method of claim 15, wherein said cell is a stem cell.

22. (Withdrawn). The method of claim 15, wherein said step (b) comprises contacting said cell with a vector that comprises a nucleic acid that encodes said at least one MIR molecule.

23. (Withdrawn). The method of claim 21, wherein said nucleic acid further comprises a nucleotide sequence that encodes a MIR-binding protein.

24. (Withdrawn). The method of claim 21, wherein said cell is comprised within a heart.